{"entity":{"id":"nct03778229","kind":"trial","name":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","aka":["SAVANNAH"],"tldr":"A phase 2 trial of Osimertinib and Savolitinib in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.","summary":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib is a phase 2 interventional study registered as NCT03778229 by AstraZeneca, with 367 participants enrolled, started 2019-01-09 and due to reach its primary completion in 2024-08-23. Interventions recorded: osimertinib, savolitinib and placebo. Results have been posted on the registry.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT03778229","url":"https://clinicaltrials.gov/study/NCT03778229"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","egfr-mutant-nsclc","met-altered-nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["osimertinib","savolitinib"],"companies":["astrazeneca","hutchmed"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct03778229-ann-oncol-2025"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03778229","phase":"2","setting":"A Phase II Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib.","sponsor":"AstraZeneca","started":"2019-01-09","startedType":"actual","yearReported":2026,"enrolled":367,"enrolledBasis":"registry","outcomes":[{"endpoint":"Objective Response Rate (ORR) by Investigator Assessment; Target Population Analysis Set","primary":true,"unit":"%","arms":[{"name":"Savo 300 mg BID + Osi","n":80,"value":56.3,"note":"95% CI 44.70 to 67.32; Figures from the ClinicalTrials.gov results section (first posted 2026-02-10), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT03778229?tab=results"},{"endpoint":"Objective Response Rate (ORR) by Investigator Assessment; 300 mg QD Safety Analysis Set","primary":true,"unit":"%","arms":[{"name":"Savo 300 mg QD + Osi","n":196,"value":31.6,"note":"95% CI 25.19 to 38.64; Figures from the ClinicalTrials.gov results section (first posted 2026-02-10), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT03778229?tab=results"},{"endpoint":"Overall Survival (OS); Target Population Analysis Set","unit":"months","arms":[{"name":"Savo 300 mg BID + Osi","n":80,"value":14.42,"note":"95% CI 11.89 to 17.87; Figures from the ClinicalTrials.gov results section (first posted 2026-02-10), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT03778229?tab=results"}]},"route":"/trials/nct03778229/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"},{"id":"savolitinib","kind":"drug","name":"Savolitinib","route":"/drugs/savolitinib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"hutchmed","kind":"company","name":"Hutchmed","route":"/companies/hutchmed/"}],"paper":[{"id":"paper-nct03778229-ann-oncol-2025","kind":"paper","name":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study","route":"/key-papers/paper-nct03778229-ann-oncol-2025/"}]}}